Investigation of the complaint kit lot including review of the qc release data, internal non conformance and stability data, did not identify any product issue.There is not a complaint trend identified for the reagent lot.Review of the customer data showed the growth curve for the complaint sample is sigmoidal and shows signs of robust amplification; however, due to the late ct, the curve was cut off before it plateaued.The shape of the curve suggests that a true target was amplified.The late ct value is indicative of a titer near the limit of detection (lod), where sample results can be expected to waiver between reactive and non-reactive.The data seems to suggest that the reactive sample has an (b)(6) titer near the lod.However, it cannot be conclusively determined if the donation was truly infected or if the reactive call was due to other factors, such as cross-contamination, non-specific amplification or non-target amplification.The udi for the cobas taqscreen mpx test, v2.0, us-ivd is (b)(4).The corresponding us kit material number is 05969484190.(b)(4).
|
A customer in (b)(6) alleged an unexpected (b)(6) result for a sample after 2 repeat, resolution testings generated (b)(6) results and serology was (b)(6).The customer decided to release the blood for use.However, it is not known how the blood was used, as that information is confidential.No harm has been alleged.
|